1. Home
  2. MXE vs ACOG Comparison

MXE vs ACOG Comparison

Compare MXE & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mexico Equity and Income Fund Inc. (The)

MXE

Mexico Equity and Income Fund Inc. (The)

N/A

Current Price

$12.61

Market Cap

54.4M

Sector

Finance

ML Signal

N/A

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.13

Market Cap

115.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXE
ACOG
Founded
1990
2000
Country
United States
Canada
Employees
N/A
57
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
115.7M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
MXE
ACOG
Price
$12.61
$5.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
2.2K
37.2K
Earning Date
01-01-0001
03-26-2026
Dividend Yield
2.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.26
$3.75
52 Week High
$14.30
$10.88

Technical Indicators

Market Signals
Indicator
MXE
ACOG
Relative Strength Index (RSI) 43.49 32.12
Support Level $12.04 $4.50
Resistance Level $12.62 $6.37
Average True Range (ATR) 0.24 0.34
MACD -0.02 -0.09
Stochastic Oscillator 42.86 12.88

Price Performance

Historical Comparison
MXE
ACOG

About MXE Mexico Equity and Income Fund Inc. (The)

Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: